Ambit Announces Initiation Of Phase 2 Cohort In MD Anderson Sponsored Study ... Wall Street Journal ... trial comparing quizartinib to standard chemotherapy in FLT3-ITD positive AML patients over the age of 18 who have relapsed from, or are refractory to, frontline chemotherapy, including those patients relapsing following a hematopoietic stem cell ... |
